证券之星消息，2月2日化学制药板块较上一交易日下跌2.74%，常山药业领跌。当日上证指数报收于 4015.75，下跌2.48%。深证成指报收于13824.35，下跌2.69%。化学制药板块个股涨跌见下表： 从资金流向上来看，当日化学制药板块主力资金净流出17.84亿元，游资资金净流入4.59亿元，散户资金 净流入13.25亿元。化学制药板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入(元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 002099 海翔药业 | | 8825.41万 | 12.82% | -5616.28万 | -8.16% | -3209.13万 | -4.66% | | 300436 | 广生堂 | 7859.33万 | 6.93% | -2678.33万 | -2.36% | -5181.00万 | -4.57% | | 600513 联环药业 | | 3551.00万 | 13.02% | -876.01万 | -3. ...

1月30日，常山药业涨5.28%，成交额15.38亿元。两融数据显示，当日常山药业获融资买入额1.04亿 元，融资偿还1.11亿元，融资净买入-781.05万元。截至1月30日，常山药业融资融券余额合计26.08亿 元。 融资方面，常山药业当日融资买入1.04亿元。当前融资余额26.08亿元，占流通市值的5.12%，融资余额 超过近一年90%分位水平，处于高位。 截至1月20日，常山药业股东户数4.14万，较上期增加2.88%；人均流通股22148股，较上期减少2.79%。 2025年1月-9月，常山药业实现营业收入6.81亿元，同比减少13.11%；归母净利润-4481.74万元，同比减 少714.77%。 分红方面，常山药业A股上市后累计派现1.81亿元。近三年，累计派现459.53万元。 融券方面，常山药业1月30日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量0.00股，融券余额0.00元，超过近一年50%分位水平，处于较高位。 资料显示，河北常山生化药业股份有限公司位于中国(河北)自由贸易试验区正定片区正定县高新技术产 业开发区南区梦龙街71号，成立日期20 ...

1月29日晚间，常山药业（300255）发布2025年业绩预告显示，预计2025年归属净利润亏损1.9亿元至 2.85亿元，同比下降14.24%至23.84%。 这已是公司连续第三年净利润亏损。值得一提的是，常山药业去年大涨2.1倍，今年至今下跌15%。 2025年三季报显示，前三季度公司营业收入6.81亿元，同比下滑13.11%；归母净利润亏损4481.74万 元。这意味着公司第四季度亏损额大幅扩大，业绩呈现加速下滑趋势。 对于业绩亏损，常山药业解释称，主要原因包括：肝素行业竞争加剧导致核心产品收入下降及毛利率低 迷；因集采品种无需大规模学术推广而进行的销售策略调整，致使销售费用大幅下降；此外，公司对个 别客户的应收账款及其他应收款计提了坏账准备，并对可能存在减值迹象的资产进行了初步评估。 常山药业表示，2025年，肝素药品行业竞争加剧，公司核心产品肝素制剂系列产品收入下降，同时受集 采及原材料价格波动等因素综合影响，毛利率维持较低水平，这是公司亏损的主要原因。 财务数据显示，2023年常山药业净利润巨亏12.4亿元，2024年公司再亏2.49亿元，2025年又亏损2亿元左 右。从营收来看，公司2022年以 ...

格隆汇1月30日丨常山药业(300255.SZ)发布2025年度业绩预告，报告期内，归属于上市公司股东的净利 润为亏损1.90亿元～2.85亿元，上年同期亏损2.49亿元；扣除非经常性损益后的净利润为亏损1.91亿元～ 2.86亿元，上年同期亏损2.86亿元。2025年，肝素药品行业竞争加剧，公司核心产品肝素制剂系列产品 收入下降，同时受集采及原材料价格波动等因素综合影响，毛利率维持较低水平，这是公司亏损的主要 原因。 ...

证券日报网讯1月29日，常山药业（300255）发布公告称，公司预计2025年度归属于上市公司股东的净 利润为-28，500万元至-19，000万元，上年同期为-24，947.77万元。 ...

北京商报讯（记者 丁宁）1月29日晚间，常山药业（300255）发布2025年业绩预告显示，预计2025年实 现归属净利润为-1.9亿元至-2.85亿元，同比下降14.24%至23.84%。 常山药业表示，2025年，肝素药品行业竞争加剧，公司核心产品肝素制剂系列产品收入下降，同时受集 采及原材料价格波动等因素综合影响，毛利率维持较低水平，这是公司亏损的主要原因。 此外，常山药业表示，2025年度，因公司主导产品那屈肝素钙注射液和达肝素钠注射液执行药品集中带 量采购政策，带量采购品种无需大规模学术推广，公司调整销售策略，优化销售团队配置，减少经销商 层级及终端维护费用，加强市场费用的精细化管理，2025年度销售费用较上年大幅度下降。 ...

Group 1 - The company Changshan Pharmaceutical (300255.SZ) has disclosed its performance forecast for the year 2025, expecting a net loss attributable to shareholders of between 190 million to 285 million yuan [1] - The net loss after deducting non-recurring gains and losses is projected to be between 191 million to 286 million yuan [1]

Core Viewpoint - The company expects a negative net profit for the fiscal year 2025, with a projected range for net profit attributable to shareholders between -285 million yuan and -190 million yuan, compared to -249 million yuan in the same period last year [1] Financial Performance - The expected net profit range for 2025 is between -286 million yuan and -191 million yuan, with the previous year's figure being -286 million yuan [1] - The company reported a net profit of -249 million yuan in the same period last year [1] Industry Context - The heparin drug industry is experiencing intensified competition, leading to a decline in revenue from the company's core heparin preparation products [1] - Factors such as centralized procurement and fluctuations in raw material prices are contributing to a low gross margin, which is a primary reason for the company's anticipated losses [1]

Financial Projections - The company expects a net profit in the range of -28,500 to -19,000 thousand CNY for 2025, representing a year-on-year decline of 14.24% to 23.84%[4] - The net profit after deducting non-recurring gains and losses is projected to be between -28,600 and -19,100 thousand CNY, with a slight increase of 0.12% to 33.30% compared to the previous year[4] - The financial data in the earnings forecast is preliminary and has not been audited by the accounting firm, with final figures to be disclosed in the 2025 annual report[8] Market Conditions - The main reason for the loss is the intensified competition in the heparin drug industry, leading to a decline in revenue from core heparin products and low gross margins due to centralized procurement and raw material price fluctuations[6] Sales and Expenses - Sales expenses are expected to decrease significantly in 2025 due to adjustments in sales strategies and optimization of sales team configurations following the implementation of centralized procurement policies[7] - The company has made provisions for credit and asset impairment based on preliminary assessments of the recoverability of accounts receivable and other receivables[7]

Group 1 - The core point of the article is that Changshan Pharmaceutical announced the release of 56,206,500 shares from pledge by its controlling shareholder, Gao Shuhua [2] Group 2 - The announcement was made on January 23, indicating a significant change in the shareholding structure [2] - The release of shares from pledge may reflect the controlling shareholder's confidence in the company's future performance [2] - This action could potentially impact the stock's liquidity and investor sentiment towards Changshan Pharmaceutical [2]